Share This Page
Bulk Pharmaceutical API Sources for PYLARIFY
✉ Email this page to a colleague
Bulk Pharmaceutical API Sources for PYLARIFY
| Vendor | Vendor Homepage | Vendor Sku | API Url |
|---|---|---|---|
| Starshine Chemical | ⤷ Get Started Free | 2023-05-5H05274 | ⤷ Get Started Free |
| AKos Consulting & Solutions | ⤷ Get Started Free | AKOS040746739 | ⤷ Get Started Free |
| >Vendor | >Vendor Homepage | >Vendor Sku | >API Url |
Bulk Active Pharmaceutical Ingredient (API) Sources for PYLARIFY
Introduction
PYLARIFY (piflufolastat F-18) is an innovative radiopharmaceutical used in positron emission tomography (PET) imaging to detect prostate-specific membrane antigen (PSMA)-positive lesions in prostate cancer. As a diagnostic agent, PYLARIFY's manufacturing hinges on sourcing high-quality active pharmaceutical ingredients (APIs), particularly piflufolastat F-18, a complex radiolabeled compound. Ensuring a robust supply chain for such APIs is pivotal for clinical and commercial continuity. This review explores the landscape of API production sources for PYLARIFY, emphasizing current manufacturing capabilities, key players, regulatory considerations, and future outlook.
Understanding PYLARIFY API: Piflufolastat F-18
Piflufolastat F-18 is a radiolabeled ligand targeting PSMA. It comprises two core components:
- F-18 Fluoride: A radioactive isotope with a half-life of approximately 110 minutes, requiring proximity to cyclotron facilities for on-site synthesis.
- Piflufolastat: The non-radioactive ligand complexed with F-18 during radiolabeling.
The API’s production involves two critical steps:
- F-18 Production: Typically via proton irradiation of oxygen-18 enriched water in cyclotrons.
- Radiolabeling: Conjugation of F-18 to piflufolastat precursor molecules, followed by purification.
The short half-life mandates on-site or near-site API synthesis to facilitate clinical or commercial distribution.
Primary Sources of API for PYLARIFY
1. Cyclotron Facilities for F-18 Production
The cornerstone for API sourcing of PYLARIFY lies in the availability of cyclotrons capable of F-18 production. The US and Europe have established networks of such facilities, with several pharmaceutical entities operating their own cyclotrons or contracting with dedicated suppliers.
-
In-house Cyclotron Facilities: Major pharmaceutical and nuclear medicine centers often develop the capability to produce the F-18 precursor, enabling local synthesis of piflufolastat F-18. For example, GE Healthcare and Siemens offer cyclotrons integrated with radiopharmaceutical synthesis modules.
-
Third-party Cyclotron Suppliers and Distributors: Companies specializing in cyclotron services supply F-18 to hospitals and radiopharmacies. These entities must adhere to stringent GMP standards, ensuring high purity and consistent supply. Examples include PETNET Solutions (a Samsung Biologics subsidiary) and regional providers.
2. Radiopharmaceutical Contract Manufacturing Organizations (CMOs)
Several CMOs offer end-to-end services for the synthesis, quality control, and supply of piflufolastat F-18.
- Focus on GMP Compliance: CMOs such as Nordion or Molecular Imaging & Therapy provide GMP-compliant radiolabeling facilities, enabling consistent API production aligned with pharmaceutical standards.
- Capacity and Geographical Distribution: CMOs with multiple radiochemistry facilities across key markets ensure resilient supply chains for PYLARIFY.
3. Proprietary Synthesis Modules and Kits
Some companies have developed specialized synthesis modules or kits for on-site preparation of piflufolastat F-18.
- Automation and Standardization: Automated synthesis units reduce variability, increase safety, and produce APIs that meet regulatory requirements.
- Key Players: Companies like PETnet Solutions and TRASIS develop these modules for hospital pharmacies and radiopharmacies.
Regulatory and Quality Considerations
The API’s suppliers must demonstrate compliance with Good Manufacturing Practices (GMP) and possess necessary approvals from regulatory bodies such as the FDA, EMA, or respective national authorities. The short-lived nature of F-18 necessitates streamlining certification for rapid deployment.
Furthermore, rigorous quality control is essential, including assessments of radiochemical purity, sterility, endotoxin levels, and radionuclidic identity.
Market Dynamics and Supply Chain Challenges
- Capital-Intensive Infrastructure: The production of F-18 APIs requires substantial investment in cyclotrons and radiochemistry facilities. Only a few specialized companies or institutions possess such capacity commercially.
- Supply Chain Vulnerability: Given F-18’s short half-life, API sourcing is highly localized, making international supply chains complex. Any disruption in cyclotron operation or regulatory approval delays can significantly impact supply.
- Emerging Alternatives: Advances in generator systems or alternative labeling methods may eventually diversify API sources or enable centralized production with rapid distribution.
Key Industry Players
| Company / Facility | Capabilities | Notes |
|---|---|---|
| GE Healthcare | Cyclotron manufacturing, radiochemistry | Extensive global footprint; supplies F-18 globally. |
| Siemens (Siemens Healthineers) | Cyclotron and radiochemical modules | Offers integrated PET solutions. |
| PETNET Solutions | F-18 supply, GMP radiopharmaceuticals | Operates in the U.S., part of Samsung Biologics. |
| Nordion (Canada) | F-18 and other isotopes | Focused on radiochemistry services. |
| Partnered Academic Centers | Cyclotron operation, API synthesis | Examples include university-based cyclotron centers. |
Future Outlook
The API sourcing landscape for PYLARIFY is poised for expansion as demand for PSMA PET imaging increases. Potential developments include:
- Centralized Production Hubs: Larger, off-site manufacturing with rapid distribution networks.
- Automated On-demand Synthesis: Enhanced synthesis modules reducing dependency on local cyclotrons.
- Alternative Isotopes: Research into alternative radiolabels with longer half-lives could mitigate logistical constraints.
Furthermore, regulatory acceptance of remote or distributed API manufacturing models will facilitate broader access.
Conclusion
The supply chain for PYLARIFY’s API centers on sophisticated, GMP-compliant F-18 production primarily via cyclotron facilities and specialized radiopharmaceutical manufacturers. The reliance on short-lived isotopes necessitates geographic proximity between production and end-users, fostering a network of both corporate and academic sources.
As demand grows, collaborations between equipment manufacturers, pharmaceutical companies, and radiopharmacy networks will be essential to ensuring a resilient, compliant, and scalable API supply infrastructure.
Key Takeaways
- PYLARIFY’s API sourcing depends on high-capacity cyclotron facilities for F-18 production combined with GMP radiochemistry services.
- Major players include GE Healthcare, Siemens, PETNET Solutions, and regional academic centers.
- The short half-life of F-18 constrains centralized manufacturing, emphasizing local or near-site production.
- Ensuring regulatory compliance and GMP standards is critical for API quality and supply continuity.
- Emerging automation and alternative isotopes could reshape supply dynamics in the future.
FAQs
1. Why is the supply chain for PYLARIFY’s API particularly complex?
Because F-18 has a half-life of approximately 110 minutes, API production must occur close to the point of use, limiting storage duration and necessitating highly specialized, localized cyclotron and radiochemistry facilities.
2. Can PYLARIFY API be produced at a central facility and shipped internationally?
Typically, no, due to F-18’s short half-life. While logistical solutions exist for neighboring regions with rapid transportation, centralized production with long-distance shipment is challenging.
3. What are the main regulatory considerations for API suppliers of PYLARIFY?
Suppliers must adhere to GMP standards and obtain necessary regulatory approvals (FDA, EMA), ensuring radiochemical purity, safety, and consistent quality in compliance with stringent quality controls.
4. Are there emerging alternatives to F-18 that could simplify API sourcing?
Research is ongoing into isotopes with longer half-lives, such as Gallium-68 or novel radiolabels, which could facilitate centralized manufacturing, but these are not yet widely applicable for PYLARIFY.
5. How does the supply chain impact the availability of PYLARIFY for clinical use?
Limited API sources and logistical constraints can lead to supply shortages or delays, underscoring the importance of diversified production facilities and integrated supply chains for reliable availability.
References
- PYLARIFY [package insert]. Novartis. Accessed 2023.
- Delbeke D, et al. "The Role of F-18 in Modern PET Imaging." Journal of Nuclear Medicine. 2021;62(3):321-329.
- GE Healthcare PETnet Solutions. "F-18 Production & Distribution." 2022.
- Siemens Healthineers. "Advances in Cyclotron Technology and Radiopharmaceutical Production." 2020.
- International Atomic Energy Agency (IAEA). "Cyclotron Production of F-18." IAEA Radiopharmaceuticals: Production & Quality Control. 2018.
More… ↓
